Summit Therapeutics (SMMT) shares are scheduled to resume trading at 3:20 pm ET, with quotes scheduled to resume at 3:15 pm ET, according to Nasdaq. Shares of Summit Therapeutics had been halted ahead of the company reporting that partner Akeso (AKESF) announced ivonescimab was approved by the Chinese Health Authorities for a second indication based on the results of the Phase 3 clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics says new ivonescimab data clinically meaningful
- Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’
- Akeso reports ivonescimab receives NMPA approval to treat NSCLC in China
- Akeso survival data for ivonescimab misses expectations, STAT says
- Summit Therapeutics sinks after STAT report on ivonescimab data